Literature DB >> 9627209

Lamotrigine toxicity secondary to sertraline.

K R Kaufman1, R Gerner.   

Abstract

Blood level monitoring helps to determine the therapeutic and toxic ranges for anticonvulsants and antidepressants. We investigated initial drug-drug interactions between lamotrigine and sertraline. We report on case histories of two epileptic patients who were initially on lamotrigine and to whom sertraline was added to control psychiatric features. In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the lamotrigine blood level with symptoms of toxicity. In case 2, a 25 mg reduction in the total daily dose of sertraline resulted in halving of the lamotrigine blood level even though the lamotrigine dosage was increased by 33%. This shows that sertraline has potent interactions with lamotrigine metabolism. The authors hypothesize that inhibition of glucuronidation is responsible. Clinicians are advised to observe for symptoms of toxicity and to do serial blood levels to monitor this interaction.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9627209     DOI: 10.1016/s1059-1311(98)80074-5

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  15 in total

Review 1.  Management of focal-onset seizures: an update on drug treatment.

Authors:  Svein I Johannessen; Elinor Ben-Menachem
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 2.  Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?

Authors:  Svein I Johannessen; Torbjörn Tomson
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 3.  The Black Book of Psychotropic Dosing and Monitoring.

Authors:  Alan F Schatzberg; DeBattista Charles
Journal:  Psychopharmacol Bull       Date:  2018-01-15

Review 4.  Drug interactions with the newer antiepileptic drugs (AEDs)--Part 2: pharmacokinetic and pharmacodynamic interactions between AEDs and drugs used to treat non-epilepsy disorders.

Authors:  Philip N Patsalos
Journal:  Clin Pharmacokinet       Date:  2013-12       Impact factor: 6.447

Review 5.  Pharmacotherapy for Focal Seizures in Children and Adolescents.

Authors:  Clare E Stevens; Carl E Stafstrom
Journal:  Drugs       Date:  2018-09       Impact factor: 9.546

Review 6.  The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders.

Authors:  G MacQueen; L Born; M Steiner
Journal:  CNS Drug Rev       Date:  2001

Review 7.  Newer anticonvulsants: comparative review of drug interactions and adverse effects.

Authors:  A Sabers; L Gram
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

Review 8.  Clinical pharmacokinetics of sertraline.

Authors:  C Lindsay DeVane; Heidi L Liston; John S Markowitz
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

9.  Pharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: Influence of polymorphism of UDP-glucuronosyltransferases and drug transporters.

Authors:  Daniela Milosheska; Bogdan Lorber; Tomaž Vovk; Matej Kastelic; Vita Dolžan; Iztok Grabnar
Journal:  Br J Clin Pharmacol       Date:  2016-05-29       Impact factor: 4.335

10.  The role of lamotrigine in the management of bipolar disorder.

Authors:  Felicity Ng; Karen Hallam; Nellie Lucas; Michael Berk
Journal:  Neuropsychiatr Dis Treat       Date:  2007-08       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.